Yes, that's interesting.

Speaking of overlaps, I'm sure that Sulzer et al. would have spotted that comment included with the AlzForum article, which mentioned a recent paper by Gendelman et al. [1]. That paper seems to have a definite overlap with their work.

[1] Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial, Gendelman et al., npj Parkinson's Disease 3, Article number: 10 (2017 March 27)

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial | npj Parkinson'''s Disease
(this is an open-access research paper)